Objectives-Induction of heme oxygenase-1 (HO-1) protects against atherosclerotic disease in part by promoting reendothelialization. As endothelial progenitor cells (EPCs) contribute to reendothelialization, we examined the role of HO-1 on bone marrow and circulating EPCs. Methods and Results-In a rabbit model of aortic balloon injury, pharmacological induction of HO-1 enhanced reendothelialization at sites with and without adjacent blood vessels, the latter indicative of a contribution by EPCs. Coinciding with maximal HO-1 induction in the injured vessel, plasma concentrations of bilirubin and the numbers of circulating progenitor cells were elevated. Both processes were abolished by cotreatment of the animals with an inhibitor of HO-1. Inducers of HO-1 promoted bone marrow cells to form progenitor cell colonies, and Flk1 ϩ /Sca-1 ϩ -cells to adhere to the luminal surface of the injured vessel. In noninjured mice, HO-1 inducers also increased bone marrow and circulating EPCs, and the ability of these cells to differentiate and form colonies. Compared to wild-type mice, bone marrow cells from HO-1 Ϫ/Ϫ mice generated fewer endothelial colony-forming cells, and HO-1 inducers failed to promote CFU-Hill colony formation. Conclusions-These findings suggest that HO-1 contributes to vascular repair by increasing circulating EPCs derived from the bone marrow. (Arterioscler Thromb Vasc Biol. 2009;29:1537-1542.) 
A therosclerotic disease is characterized by heightened inflammation and oxidative stress. 1 As a result, there is considerable interest in compounds with antiinflammatory and antioxidant properties as potential novel drugs against the disease. Recently, a class of sulfur-containing phenols, structurally based on probucol, has been shown to inhibit atherosclerotic vascular diseases by inducing heme oxygenase-1 (HO-1) in arterial cells. 2 HO-1 is the inducible form of heme oxygenases that metabolize heme to carbon monoxide (CO), iron, and biliverdin, which is converted to bilirubin by biliverdin reductase. 3 Mounting evidence suggests that upregulation of HO-1 protects against vascular diseases, including atherosclerosis and intimal hyperplasia. 4 HO-1 is thought to protect via promoting reendothelialization, inducing antiinflammatory activities, inhibiting smooth muscle cell proliferation, regulating vascular tone, and by increasing cellular antioxidant activities. 4 Of these beneficial activities, promotion of reendothelialization could conceivably play a primary protective role. This is because the functional endothelium regulates vascular homeostasis, by controlling endothelial adhesion of inflammatory cells 5 and proliferation of smooth muscle cells. 6 Reendothelialization of a denuded arterial surface is achieved by the migration and proliferation of endothelial cells from the injury border zone, or from adjacent branching blood vessels. 7 In addition, bone marrow-derived endothelial progenitor cells (EPCs) can contribute to reendothelialization. 8 Whether increased recruitment of EPCs is involved in the promotion of reendothelialization by HO-1 is presently not known. We therefore investigated this possibility, using probucol and its derivative succinobucol as pharmacological inducers of HO-1, and mice deficient in HO-1 (HO-1 Ϫ/Ϫ ) as a molecular tool. The results obtained show that HO-1 increases the numbers of circulating and bone marrow early and late outgrowth progenitor cells, and enhances the maturation of bone marrow-derived progenitor cells. These novel activities likely contribute to the ability of HO-1 to enhance reendothelialization and hence the repair of injured blood vessels.
Materials and Methods
An expanded Materials and Methods section is described in the supplemental materials (available online at http://atvb.ahajournals.org).
Animal Models
Rabbits fed 1% probucol (Medichem) or 0.02% succinobucol (Chemaphor) underwent aortic balloon injury. Intimal hyperplasia and reendothelialization were evaluated by immunohistochemistry. Damaged and undamaged aorta were also stained for Sca-1 ϩ , Flk1 ϩ , CD31 ϩ , and assessed for heme oxygenase mRNA and activity. Ageand gender-matched heme oxygenase-1 knock out (HO-1 Ϫ/Ϫ ) and appropriate wild-type (HO-1 ϩ/ϩ ) mice were fed normal chow Ϯ0.02% succinobucol (wt/wt) for 2 weeks before bone marrow or blood was collected.
Flow Cytometry
Cells obtained from peripheral blood collected from rabbits 4 days after balloon injury, or blood and bone marrow from noninjured mice, were analyzed in a FACS Caliber flow cytometer (Becton Dickinson). Details are provided in supplemental materials.
Culture of ECFCs and CFU-Hill
Mouse endothelial colony-forming cells (ECFCs) were prepared from bone marrow mononuclear cells isolated from uninjured mice. Bone marrow cells isolated from femurs of uninjured mice or rabbits 4 days post injury were used to culture CFU-Hill (see supplemental materials).
Statistical Analyses
Data are expressed as meansϮSEM and analyzed as described in the supplemental materials.
Results

Succinobucol Inhibits Intimal Hyperplasia, Promotes Reendothelialization, and Induces HO-1
Rabbits matched for baseline plasma cholesterol were fed a limited amount (100 g/d) of standard chow Ϯ1% probucol (positive control) or 0.02% (wt/wt) succinobucol for 9 weeks, with endothelial denudation of the abdominal aorta performed at the end of week 3. The dose of the drugs used, based on previous studies, 9, 10 resulted in drug concentrations of 11Ϯ1.5 and 9.1Ϯ5.4 mol/L in plasma, and 579Ϯ106 and 478Ϯ32 nmol/mg protein in the aorta for probucol and succinobucol, respectively. Similar to probucol 9 and as expected from its chemical structure, 2 succinobucol significantly decreased intimal hyperplasia, as judged by the intimato-media ratio ( Figure 1A and 1B) . In contrast to probucol, succinobucol did not decrease plasma cholesterol ( Figure  1C ). Both agents did not affect aortic cholesterol ( Figure 1D ).
Increasing evidence points to a key role for HO-1 in the control of intimal hyperplasia, 11 and probucol protects against intimal hyperplasia via induction of HO-1 in affected vessels. 2 Similar to probucol, succinobucol significantly increased HO-1 mRNA ( Figure 2A ) and HO activity ( Figure 2B ) in rabbit aortas 4 days after injury. At this time there was no change in HO-1 mRNA in circulating leukocytes and a trend (Pϭ0.059) toward increased HO-1 mRNA in bone marrow cells (supplemental Figure I ). Both drugs increased plasma bilirubin, an effect abolished by cotreatment of the animals with the HO inhibitor tin protoporphyrin-IX (SnPP; Figure 2C ).
The promotion of reendothelialization regulates the ability of probucol to protect against intimal hyperplasia in response to arterial injury. 2 Reendothelialization results from the mi-gration and proliferation of endothelial cells from the injury border zone or from branching blood vessels adjacent to the site of injury. 12 Indeed, 6 weeks after injury, the previously denuded aortic surface is partly covered by endothelial cells that originate from branch orifices in a process promoted by probucol. 9 The present study confirms this finding and extends it to succinobucol ( Figure 3A ), as assessed by the length of endothelium covered by CD31 ϩ -cells from the branch orifice (supplemental Figure II) . 2 In addition, patches of intact endothelium were present in nonbranched areas of the previously denuded artery, 3 10 mm away from branch orifices and the injury zone. Probucol and succinobucol also significantly promoted reendothelialization at these nonbranched sites ( Figure 3B , supplemental Figure II ). Probucol-enhanced reendothelialization at branched and nonbranched sites was inhibited completely by cotreatment of the rabbits with SnPP ( Figure 3C and 3D). Together, these results suggest that EPCs may contribute to the regeneration of an intact endothelium and that inducers of HO-1 activity enhance this process.
Induction of HO-1 Increases Circulating Progenitor Cells
Circulating cells derived from the bone marrow and exhibiting phenotypic features of endothelial cells are capable of homing to sites of endothelial disruption and incorporating into nascent endothelium. 13 These progenitor cells commonly express the stem cell antigen, Sca-1, a well-recognized marker of hematopoietic stem cells. 14 Sca-1 ϩ cells adhered to the denuded vessel surface 4 days postinjury, and probucol and succinobucol significantly increased the number of these cells ( Figure 4A ). Some of the endothelial-like cells also stained positive for Flk1, another endothelial marker ( Figure  4B ). The observed probucol-mediated increase in Sca-1 ϩ and Flk1 ϩ cells was abolished by cotreatment of the animals with SnPP ( Figure 4C and 4D), suggesting that it was dependent on HO activity. In contrast, at this time point none of the endothelial-like cells stained positive for CD31, RAM-11, or F4/F80 (not shown). Also, probucol and succinobucol did not increase the number of T and B cells, as assessed by CD3 ϩ and CD19 ϩ staining, respectively (supplemental Figure III ), suggesting that these cells are not derived from CFU-Hill colonies, which are known to be composed of T-and B-cells, as well as myeloid cells. 15 This excludes the possibility that an increase in these immune cells was responsible for the increase in Sca1 ϩ cells seen in animals treated with the HO-1 inducers. Together, these results suggest that the promotion of reendothelialization by probucol and succinobucol is HO-1dependent and involves the participation of progenitor cells.
Progenitor cells that attach to the surface of injured blood vessels can originate from a subpopulation of circulating, bone marrow-derived cells. 13 We therefore collected peripheral blood from rabbits 4 days after aortic injury and assessed mononuclear cells for the presence of Sca-1 and Flk1. This time point was chosen because HO-1 is maximally expressed in the rabbit vessel wall 4 days after injury, 16 and this coincides with maximal number of circulating progenitor cells (Supplemental Figure IV) . Compared to control, rabbits treated with probucol or succinobucol had significantly increased numbers of Sca-1 ϩ -and Flk1 ϩ -cells ( Figure 5A , C), with isotype controls showing minimal staining (Supplemental Figure V) . Importantly, there was no significant difference in the total white cell count between control and drug-treated animals ( Supplemental Table) .
We next cultured isolated blood mononuclear cells for 7 days under conditions that promote growth of progenitor cells, defined here as adherent cells positive for Dil-acLDL uptake plus FITC-isolectin. Probucol and succinobucol significantly increased acLDL ϩ -and isolectin ϩ -cells ( Figure 5B,  D) , an effect inhibited completely by SnPP ( Figure 5C, D) . These data suggest that induction of HO-1 is critical for the increase in circulating progenitor cells, and that the latter does not simply reflect an inflammatory response to the injury.
HO-1 Increases Bone Marrow EPC Numbers and Maturation
Two different populations of cells are thought to contribute to the repair of damaged blood vessels. CFU-Hill enhance angiogenesis in a paracrine manner, [17] [18] [19] whereas late outgrowth endothelial cells (or ECFCs) directly participate in vasculogenesis. 19 Rabbit bone marrow was collected 4 days after aortic injury, and cells were cultured for 6 days under endothelial cell growth conditions. The typical CFU formed presented as a central cord of cells with elongated spindleshaped cells sprouting at the periphery of the colony typical of CFU-Hill (not shown). Initial characterization revealed that the majority of CFU cells expressed the endothelial cell markers Flk1 and von Willebrand factor, with less than half of the cells showing weak staining for CD14 (a monocytic marker), and no cells staining for RAM11 (a macrophage marker; supplemental Figure VI ). In addition, these cells stained positive for isolectin (not shown). Collectively, these data suggest that the majority of cells in these CFU are CFU-Hill, as demonstrated previously. 20 Importantly, treatment of rabbits with either of the 2 HO-1 inducers significantly increased the number of CFU compared to control ( Figure 5E ). We next investigated the involvement of HO-1 in the formation of CFU-Hill and ECFCs in noninjured wild-type (HO-1 ϩ/ϩ ) and HO-1 Ϫ/Ϫ miceϮsuccinobucol supplementation for 2 weeks. CFU-Hill were characterized as cells possessing nonspecific esterase activity, expressing Flk1, CD34, CD45 and CD115, and not being able to form tubules when plated on matrigel, whereas ECFCs formed secondary colonies on replating, lacked nonspecific esterase activity, formed tubules, and expressed Flk1, CD34, and CD144 but not CD45 and CD115 (supplemental Figure VII) . 18 Drug treatment resulted in plasma succinobucol concentrations of 3.4Ϯ1.9 mol/L (meanϮSD, nϭ10; no difference between HO-1 ϩ/ϩ and HO-1 Ϫ/Ϫ mice). Succinobucol did not affect blood pressure (95Ϯ9 versus 94Ϯ7 mm Hg for control and succinobucol, respectively; meanϮSD, nϭ11) and total, HDL, and LDL cholesterol (not shown). Compared to HO-1 ϩ/ϩ mice, bone marrow cells from HO-1 Ϫ/Ϫ mice showed a significantly impaired ability to form CFU-Hill ( Figure 6A ) and ECFCs ( Figure 6B ). Consistent with a role for HO-1 in the formation of progenitor cells, succinobucol treatment of mice increased the number of bone marrow-derived CFU-Hill in wild-type (HO-1 ϩ/ϩ ; Figure 6C ) but not HO-1 Ϫ/Ϫ mice ( Figure 6D) . Similarly, treatment of wild-type mice with the HO-1 inducer also tended to increase ECFCs (Pϭ0.058; Figure 6E ). This was associated with an increase in the number of progenitor cells in freshly isolated bone marrow ( Figure 6F and 6G) and circulating cells ( Figure 6H ), including nonhematopoietic (CD34 ϩ /Flk1 ϩ /CD45 Ϫ ) and hematopoietic (CD34 ϩ /Flk1 ϩ /CD45 ϩ ) cells (supplemental Figure  VIII) that are thought to contribute to reendothelialization. 21, 22 Compared to HO-1 ϩ/ϩ mice, CFU-Hill obtained from the bone marrow of HO-1 Ϫ/Ϫ mice after 6 days of culture were less mature, as assessed by Flk1 and VEcadherin staining 23 (supplemental Figure IX) .
Discussion
Endothelial injury promotes the initiation and progression of atherosclerosis and related diseases, and reendothelialization of the damaged artery is critical for repair. Previously, we have shown that this repair is enhanced via induction of HO-1 by probucol and related compounds, 2, 9, 16 and others have established that intact endothelial cells adjacent to damaged sites participate in endothelial regeneration. 6 A novel finding of the present study is that pharmacological inducers of HO-1 also effectively promote reendothelialization in areas distant to intact endothelium, suggesting that HO-1 aids the repair process by increasing EPCs. It is now increasingly appreciated that EPCs contribute to reendothelialization. 24 What is new, however, is that HO-1 increases the number of bone marrow and circulating progenitor cells.
The evidence to support a role for HO-1 in increasing both CFU-Hill and ECFCs capable of vascular repair is based on pharmacological and molecular studies. Thus, the increase in circulating progenitor cells was blocked when rabbits were treated with a HO inhibitor, indicating a requirement for enzyme activity. As blockade of HO activity also prevents HO-1 inducers from inhibiting intimal hyperplasia, 2 the present results directly link the HO-1-dependent increase in circulating progenitor cells to enhanced vascular repair. This interpretation is supported by the observation that HO-1 inducers increased the number of Flk1 ϩ -and Sca-1 ϩ -cells in the injured aorta, and that this increase was dependent on HO activity. Although we are unaware of previous studies describing Sca-1 staining of rabbit tissue, we consistently observed such staining in rabbit aortas and circulating cells. Our studies in noninjured mice show that HO-1 increases bone marrow and circulating ECFCs. Pharmacological HO-1 inducers failed to enhance bone marrow CFU-Hill in HO-1 Ϫ/Ϫ mice, and these animals also showed a decreased ability to form ECFCs compared to wild-type controls. Together, these results indicate an intrinsic role for HO-1 in regulating bone marrow ECFCs and CFU-Hill. Whether this is attributable to HO-1 directly increasing the mobilization of progenitor cells remains to be established, although others have reported HO-1 to be important in the mobilization of progenitor cells from the bone marrow after ischemic hind limb injury. 25 To clarify this issue further, bone marrow transplant experiments tracking specifically labeled pools of cells will need to be carried out.
The number of circulating EPCs inversely correlates with the risk for atherosclerosis 26 and the extent of ischemia after stroke or myocardial infarction. 27 Several compounds, including erythropoietin 28 and statins, 29 promote EPC mobilization and increase circulating EPCs. Interestingly, erythropoietin 30 and statins 31 can induce HO-1 expression, raising the possibility that their ability to mobilize EPCs is mediated at least in part via HO-1 induction. However, the ability of HO-1 to increase ECFCs reported here is unlikely mediated by erythropoietin, because HO-1 Ϫ/Ϫ mice have increased circulating erythropoietin compared to HO-1 ϩ/ϩ animals, and succinobucol decreased circulating erythropoietin (data not shown).
The ability of HO-1 to promote reendothelialization is reminiscent of the ability of the enzyme to impact on angiogenesis. For example, adenoviral delivery of HO-1 improves blood flow to ischemic limbs, an effect abolished by HO inhibition. 32 Vascular endothelial growth factor increases cellular HO-1 activity, and HO-1 inhibition abrogates angiogenesis driven by vascular endothelial growth factor. 33 This suggests that HO-1 may act as an amplifying factor for angiogenesis. Deshane et al 34 reported inhibition of HO-1 to prevent in vitro endothelial tube formation induced by SDF-1, a chemokine that contributes to neovascularization and plays a major role in the migration, recruitment, and retention of EPCs to sites of injury. These authors also reported the migratory potential of EPCs from HO-1 Ϫ/Ϫ mice to be impaired, and HO-1 to be required for EPC recruitment and wound healing in a retinal vascular repair model. 34 Interestingly, mechanistic studies pointed to an important role for SDF-1-mediated induction of HO-1 and CO, yet SDF-1 expression was similar in HO-1 Ϫ/Ϫ and HO-1 ϩ/ϩ mice, 34 a finding confirmed by us (data not shown). However, a recent study reported HO-1 overexpression to increase, and HO-1 deficiency to decrease, SDF-1 in ischemic hearts. 35 These observations suggest that HO-1-inducing drugs may promote reendothelialization via changing SDF-1 expression. Together, these findings indicate a role for HO-1 at several steps in EPC-mediated vascular repair, ie, the growth and maturation of bone marrow EPCs, as well as their homing to and local migration at sites of injury.
Kong and coworkers previously reported reendothelialization to be enhanced and intimal thickening to be inhibited in injured vessels treated in situ with exogenous EPCs. 20 In that study, no additional reduction in hyperplasia was seen in vessels transplanted with HO-1-overexpressing compared to control EPCs. 20 In contrast, we observed a clear benefit of HO-1 and HO-1 inducers on endogenous EPCs, including increased adherence of progenitor cells to the damaged artery early after injury, and increased reendothelialization of nonbranched areas. A benefit may have been masked in the previous study where comparatively (to endogenous EPCs) large numbers of EPCs were added locally, causing a massive (ie, 300%) increase in reendothelialization. 20 Indeed, the work of Deshane et al shows that HO-1 is important in EPC homing to and migration at the injured blood vessel. 34 This is the first study to demonstrate that succinobucol induced HO-1 in an injured artery, and that this increases EPC numbers and contributes to the reendothelialization of the damaged vessel. In light of our previous studies, 2 these findings suggest that induction of HO-1 is a major mode of action of succinobucol. Succinobucol is an orally active and metabolically stable derivative of probucol, currently undergoing clinical trial as a novel antidiabetic agent. 36 The drug reduces atherosclerotic lesions in different experimental models. 10 In humans, succinobucol improves coronary artery lumen size after percutaneous coronary intervention, 37 and it significantly reduces atheroma compared to baseline (but not placebo). 38 Although the drug missed its primary composite end point in the recently completed Phase III trial, succinobucol, in conjunction with current standard of care, did show benefit in the "hard" cardiovascular end points, such as death, heart attack, and stroke, and it substantially decreased new onset of type 2 diabetes. 38 The ability to induce HO-1 can explain the beneficial activities of succinobucol against atherosclerosis and restenosis. 2 Similarly, it may help elucidate the potential antidiabetic action of succinobucol and related compounds. 39 Diabetes is associated with a decrease in circulating EPCs and EPC function 40 that may contribute to vascular disease. 41 Also, HO-1 induction is known to attenuate inflammation and oxidative stress 3 thought to contribute to diabetes. 42 It remains unclear how HO-1 increases ECFCs, although enzyme activity is required ( Figure 5 ). Product(s) of HO-1 action may be involved. In this context, addition of COreleasing molecules to endothelial cells or arterial rings in vitro promotes capillary sprouting, even under conditions where endogenous HO-1 is absent or inhibited. 34, 43 The CO-mediated promotion of an angiogenic response may occur via synthesis of vascular endothelial growth factor. 43 In contrast to CO, bilirubin does not share the angiogenesis promoting activity. 34 Also, preliminary data suggest that bilirubin or CO-releasing molecule-2 do not affect the formation of CFU-Hill from bone marrow cells (not shown).
In conclusion, reendothelialization after vascular injury occurs via a HO-1-dependent pathway that involves ECFCs and can be enhanced by HO-1 inducers, such as succinobucol and related compounds. Our results suggest that targeting HO-1 is a therapeutically feasible approach to enhance the repair of damaged blood vessels and possibly other tissues.
